Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.45 USD | -0.43% | +10.41% | +87.09% |
Financials (USD)
Sales 2024 * | 604K | Sales 2025 * | 8.03M | Capitalization | 297M |
---|---|---|---|---|---|
Net income 2024 * | -99M | Net income 2025 * | -93M | EV / Sales 2024 * | 491 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 36.9 x |
P/E ratio 2024 * |
-2.97
x | P/E ratio 2025 * |
-3.79
x | Employees | 122 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals, Inc.
1 day | -0.43% | ||
1 week | +10.41% | ||
1 month | -17.51% | ||
3 months | +112.43% | ||
6 months | +161.92% | ||
Current year | +87.09% |
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 11.45 | -0.43% | 193,395 |
24-04-29 | 11.5 | +8.80% | 342,147 |
24-04-26 | 10.57 | +4.40% | 196,113 |
24-04-25 | 10.12 | -0.34% | 154,741 |
24-04-24 | 10.16 | -2.03% | 246,812 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+87.09% | 297M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- INO Stock